Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the independent Data Monitoring Committee (DMC) has completed the single ad hoc interim analysis of the pivotal Phase 3 SIERRA study of Iomab-B...

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.

Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.40, moving -1.04% from the previous trading session.

Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.11, marking a +0.63% move from the previous day.

Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know

NEW YORK, Dec. 9, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Targeted Radiopharmaceuticals Summit being held virtually December 8th – 10th. During the event, Dale Ludwig, Ph.D....

Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were...

Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting

Additional early stage results continue to be promising. The cash balance is adequate.

Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab...

Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.

Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

NEW YORK, Nov. 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Avinash Desai, MD, to the position of Executive Vice President of Clinical Development, Operations and Medical Affairs, effective immediately. In...

Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs

NEW YORK, Nov. 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, November 19, 2020. During the event, Actinium's...

Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.

Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology (ASH)...

Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation at the 2020 American Society of...

Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities...

Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

Their targeted approach to bone marrow transplant conditioning has shown early signs of significantly improving on the poor outcomes seen with current non-targeted therapies.

Actinium Pharmaceuticals: Far Enough Along For A Small Bet

Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?

Is  (ATNM) Outperforming Other Medical Stocks This Year?

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options

As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).

Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?

Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Alpine Immune Sciences

Pacira Pharmaceuticals

Telesis Bio Inc

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

News for Actinium Pharmaceuticals Stock (ATNM)